RNS Number : 6784K Renalytix PLC 15 April 2024 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD
RNS Number : 6091K Stifel Nicolaus Europe Limited 15 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 5019K Renalytix PLC 12 April 2024 S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares: Renalytix PLC 1b. Please indicate if the issuer is a non- UK issuer (please mark with an "X"
RNS Number : 3586K Renalytix PLC 12 April 2024 Renalytix plc ("Renalytix" or the "Company") Rule 2.9 Announcement LONDON and SALT LAKE CITY - 12 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , in accordance with Rule 2.9 of the City Code on Takeovers and Mergers and further
RNS Number : 0147K Stifel Nicolaus Europe Limited 10 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 0298K Renalytix PLC 10 April 2024 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY - 10 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of principal and interest amount due under the
RNS Number : 8412J Stifel Nicolaus Europe Limited 09 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “ Ordinary Shares ”) (the “
RNS Number : 6587J Stifel Nicolaus Europe Limited 08 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 6496J Renalytix PLC 08 April 2024 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
